Publications by authors named "Mohamed AbdelMohsen"

Purpose Of Review: People with HIV (PWH) experience premature aging and an elevated risk of age-related comorbidities, even with viral suppression through antiretroviral therapy (ART). We examine gastrointestinal disruptions, specifically impaired intestinal barrier integrity and microbial dysbiosis, as contributors to these comorbidities.

Recent Findings: HIV infection compromises the intestinal epithelial barrier, increasing permeability and microbial translocation, which trigger inflammation and cellular stress.

View Article and Find Full Text PDF
Article Synopsis
  • - Viremic non-progressors (VNPs) are a rare group of HIV-1 individuals who maintain normal CD4 T cell counts despite high viral loads, resembling natural hosts of simian immunodeficiency virus, but the reasons for this are not fully understood.
  • - A study using single-cell and multiomics methods examined 16 VNPs and 29 HIV+ progressors, revealing genetic factors like CCR5Δ32 heterozygosity and lower CCR5 expression, alongside reduced intestinal disruption and immune responses in VNPs.
  • - The research highlights various traits contributing to the immune stability in VNPs, indicating important insights for potential HIV treatment strategies in the future.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to explore how consistent and stable liver standardized uptake values (SUV) are across different cancer types while considering normalization methods and blood glucose levels.
  • It involved 207 patients with breast, lymphoma, lung, and bone-metastasis cancer, using multiple PET/CT imaging systems after administering a dose of 18F-FDG.
  • Findings showed non-significant differences in SUV measurements among the scanners, highlighting the need for careful selection of normalization methods before clinical use, with body surface area normalization potentially offering the best correlation.
View Article and Find Full Text PDF
Article Synopsis
  • The review investigates different biological molecules in bodily fluids that could serve as biomarkers for the HIV post-treatment controller (PTC) phenotype and the timing of viral rebound after stopping antiretroviral therapy (ART).
  • It highlights recently discovered viral components and host factors, such as specific antibodies and inflammation markers, that are crucial for understanding the PTC phenotype and predicting viral rebound following ART interruption.
  • The authors propose a comprehensive model that incorporates multiple biomarkers to better predict the PTC phenotype and assist in developing new curative treatments for those who do not achieve this phenotype.
View Article and Find Full Text PDF

Hyperglycemia, and exacerbation of pre-existing deficits in glucose metabolism, are manifestations of the post-acute sequelae of SARS-CoV-2. Our understanding of metabolic decline after acute COVID-19 remains unclear due to the lack of animal models. Here, we report a non-human primate model of metabolic post-acute sequelae of SARS-CoV-2 using SARS-CoV-2 infected African green monkeys.

View Article and Find Full Text PDF
Article Synopsis
  • Many patients treated with FDA-approved CAR T cells see their disease progress, especially with solid cancers and certain types of blood cancers like T cell lymphomas.
  • A major challenge in adoptive T cell therapies is the dysfunction of CAR T cells, which struggle to expand and last after being infused.
  • The study reveals that knocking out the CD5 gene using CRISPR-Cas9 can improve the antitumor abilities of CAR T cells by enhancing their function and persistence, suggesting CD5 as a key target for improving T cell therapies.
View Article and Find Full Text PDF
Article Synopsis
  • Host metabolic issues, particularly in tryptophan metabolism, are linked to the severity of COVID-19 and long COVID symptoms.
  • People with HIV also experience similar metabolic problems, raising questions about their risk for severe COVID-19 outcomes.
  • Research on samples from people living with HIV indicates that certain metabolic changes may predict higher risks for severe COVID-19 and long COVID, suggesting a need for further study.
View Article and Find Full Text PDF
Article Synopsis
  • Antiretroviral therapy (ART) has extended the lives of individuals with HIV-1, but ongoing treatment is necessary, making research into potential cure strategies essential, including using analytic treatment interruption (ATI) to evaluate viral rebound.
  • A study examined biomarkers in HIV controllers—those who maintain low HIV levels without ART—looking at immune, glycomic, lipidomic, and metabolomic markers to determine their effect on outcomes during ATI.
  • Results indicated that higher levels of specific immune cells and certain glycan types were linked with quicker HIV rebound, while specific lipids and glycan structures were associated with delaying rebounding, suggesting complex interactions in the body's response to HIV.
View Article and Find Full Text PDF

HIV infection is associated with gut dysbiosis, and microbiome variability may affect HIV control when antiretroviral therapy (ART) is stopped. The TLR7 agonist, vesatolimod, was previously associated with a modest delay in viral rebound following analytical treatment interruption in HIV controllers (HCs). Using a retrospective analysis of fecal samples from HCs treated with vesatolimod or placebo (NCT03060447), people with chronic HIV (CH; NCT02858401) or without HIV (PWOH), we examined fecal microbiome profile in HCs before/after treatment, and in CH and PWOH.

View Article and Find Full Text PDF
Article Synopsis
  • * The study analyzed IgG N-glycans in over 1200 individuals, revealing that PLWH show more significant glycan changes associated with aging and inflammation compared to those without HIV.
  • * These glycan alterations are linked to higher inflammation markers and worse health outcomes, suggesting they could be used to develop new biomarkers to help monitor and prevent age-related diseases in PLWH.
View Article and Find Full Text PDF

Aberrant glycosylation is a crucial strategy employed by cancer cells to evade cellular immunity. However, it's unclear whether homologous recombination (HR) status-dependent glycosylation can be therapeutically explored. Here, we show that the inhibition of branched N-glycans sensitizes HR-proficient, but not HR-deficient, epithelial ovarian cancers (EOCs) to immune checkpoint blockade (ICB).

View Article and Find Full Text PDF

Since the onset of the COVID-19 pandemic, significant progress has been made in developing effective preventive and therapeutic strategies against severe acute SARS-CoV-2 infection. However, the management of Long COVID (LC), an infection-associated chronic condition that has been estimated to affect 5-20% of individuals following SARS-CoV-2 infection, remains challenging due to our limited understanding of its mechanisms. Although LC is a heterogeneous disease that is likely to have several subtypes, immune system disturbances appear common across many cases.

View Article and Find Full Text PDF

Background: People living with HIV (PLWH), even when viral replication is controlled through antiretroviral therapy (ART), experience persistent inflammation. This inflammation is partly attributed to intestinal microbial dysbiosis and translocation, which may lead to non-AIDS-related aging-associated comorbidities. The extent to which living with HIV - influenced by the infection itself, ART usage, sexual orientation, or other associated factors - affects the biological age of the intestines is unclear.

View Article and Find Full Text PDF

BACKGROUNDIdentifying factors that predict the timing of HIV rebound after treatment interruption will be crucial for designing and evaluating interventions for HIV remission.METHODSWe performed a broad evaluation of viral and immune factors that predict viral rebound (AIDS Clinical Trials Group A5345). Participants initiated antiretroviral therapy (ART) during chronic (N = 33) or early (N = 12) HIV infection with ≥ 2 years of suppressive ART and restarted ART if they had 2 viral loads ≥ 1,000 copies/mL after treatment interruption.

View Article and Find Full Text PDF
Article Synopsis
  • Triple negative breast cancer (TNBC) is a highly aggressive cancer subtype with poor survival rates, prompting interest in less toxic metal-based therapies like copper complexes.
  • This study investigates the effects of copper(I) nicotinate (CNC) on TNBC cell lines, focusing on its influence on the Notch1 signaling pathway and its potential to induce apoptotic cell death alongside the traditional drug doxorubicin (Doxo).
  • While CNC demonstrated promising anti-cancer activities by modulating the Notch1 pathway differently depending on the cell type and dosage, these factors must be carefully considered for effective treatment strategies.
View Article and Find Full Text PDF

Background: People with HIV (PWH), even with controlled viral replication through antiretroviral therapy (ART), experience persistent inflammation. This is partly due to intestinal microbial dysbiosis and translocation. Such ongoing inflammation may lead to the development of non-AIDS-related aging-associated comorbidities.

View Article and Find Full Text PDF

Ovarian cancer (OC) is a lethal gynecologic malignancy, with modest responses to CPI. Engagement of additional immune arms, such as NK cells, may be of value. We focused on Siglec-7 as a surface antigen for engaging this population.

View Article and Find Full Text PDF

Colorectal cancer (CRC) is a significant global health concern. Microbial dysbiosis and associated metabolites have been associated with CRC occurrence and progression. This study aims to analyze the gut microbiota composition and the enriched metabolic pathways in patients with late-stage CRC.

View Article and Find Full Text PDF

Post-acute sequelae of COVID-19 (PASC, "Long COVID") pose a significant global health challenge. The pathophysiology is unknown, and no effective treatments have been found to date. Several hypotheses have been formulated to explain the etiology of PASC, including viral persistence, chronic inflammation, hypercoagulability, and autonomic dysfunction.

View Article and Find Full Text PDF
Article Synopsis
  • - The study examines how HIV persists in people on antiretroviral therapy (ART) by analyzing the behavior of different CD4+ T cell subsets in 37 male participants, focusing on HIV DNA and cell turnover rates.
  • - It was found that HIV levels decrease in more differentiated T cell subsets but not in less-differentiated ones, and the turnover rate of these memory cells is significantly faster than the rate at which HIV is cleared.
  • - A mathematical model suggests that HIV DNA is generated through cellular proliferation and differentiation, indicating that targeting these processes could potentially reduce HIV levels significantly over time.
View Article and Find Full Text PDF

People with HIV (PWH) experience an increased vulnerability to premature aging and inflammation-associated comorbidities, even when HIV replication is suppressed by antiretroviral therapy (ART). However, the factors that contribute to or are associated with this vulnerability remain uncertain. In the general population, alterations in the glycomes of circulating IgGs trigger inflammation and precede the onset of aging-associated diseases.

View Article and Find Full Text PDF

The epidemy of metabolic syndrome (MetS) is typically preceded by adoption of a "risky" lifestyle (e.g., dietary habit) among populations.

View Article and Find Full Text PDF

Harnessing the immune system to combat disease has revolutionized medical treatment. Monoclonal antibodies (mAbs), in particular, have emerged as important immunotherapeutic agents with clinical relevance in treating a wide range of diseases, including allergies, autoimmune diseases, neurodegenerative disorders, cancer, and infectious diseases. These mAbs are developed from naturally occurring antibodies and target specific epitopes of single molecules, minimizing off-target effects.

View Article and Find Full Text PDF

Background: Iron overload can result in grave consequences in thalassemic patients, despite the availability of iron chelators. Therefore, alternative pathways aiming to reduce iron toxicity are currently investigated. Among which, reduction of iron absorption through control of hepcidin production appears to be promising.

View Article and Find Full Text PDF